RNA m6A & Inosine Detection
What Is RNA m6A & Inosine Detection?
RNA m6A & Inosine Sequencing is an advanced epitranscriptomic profiling method that detects and quantifies N6-methyladenosine (m6A) and inosine (A-to-I editing) at single-base resolution across the transcriptome. These RNA modifications play critical roles in regulating RNA stability, splicing, localization, and translation, and are increasingly recognized as key drivers in cancer, neurological disorders, immune regulation, and aging.
At AUGenomics, we use AlidaBio’s EpiPlex™ platform, which redefines RNA modification detection through proximity-based barcoding and non-antibody binders (NABs). Unlike traditional MeRIP-seq (antibody-based RNA immunoprecipitation), EpiPlex enables:
-
Multiplexed modification detection within a single experiment.
-
Direct, non-antibody detection with high specificity and stability.
-
Accurate quantification of modification density using spike-in controls.
The workflow combines conversion-free RNA capture, deep NGS, and machine learning-based analysis (EpiScout™) to achieve high sensitivity, reproducibility, and site-specific resolution. This allows researchers to map the epitranscriptome with unprecedented clarity and uncover disease-relevant RNA modification patterns.
Advantages of RNA m6A & Inosine Detection
01
High Specificity: Uses tailored non-antibody binders to accurately identify m6A and inosine sites.
02
Single-Base Resolution: Captures modification sites with base-level precision rather than broad peaks.
03
Multiplex Detection: Profiles multiple RNA modifications in a single run for comprehensive analysis.
04
Quantitative Insights: Spike-in controls enable relative quantitation of modification abundance across samples.
05
Low RNA Input: Requires only 20 ng poly(A) RNA or 250 ng total RNA, making it compatible with scarce samples.
06
High Throughput: Capable of processing 8–24 samples per kit with only 3 hours of hands-on time.
07
Machine Learning Analysis: EpiScout software validates modification sites using molecular patterns (e.g., DRACH motif for m6A, A>G signature for inosine).
08
Disease-Relevant Data: Detects site-specific modulations in disease progression and response to treatment.
09
Cross-Species Flexibility: Applicable to a wide range of sample types and species.
RNA modification sequencing is a powerful tool for uncovering the functional impact of RNA chemical modifications. Common applications include:
-
Cancer Research: Mapping m6A and inosine changes in tumor RNA to identify biomarkers and therapeutic targets.
-
Neurological Disorders: Investigating RNA editing and methylation patterns associated with brain function and neurodegenerative diseases.
-
Immunology and Autoimmunity: Profiling RNA modifications that regulate immune activation, tolerance, and disease.
-
Aging and Metabolism Studies: Understanding how epitranscriptomic changes influence cellular aging and metabolic regulation.
-
Drug Development: Identifying RNA modification sites responsive to inhibitors of m6A “writers” or RNA editing enzymes.
-
Pathway Discovery: Linking RNA modification patterns to gene regulation, splicing, and translation pathways.
-
Agricultural Biotechnology: Exploring RNA modification dynamics that influence crop yield and stress resistance.
What is RNA m6A & Inosine Detection Used For?
RNA m6A & Inosine Detection with AUGenomics
Sample Submission
-
Submit high-quality total RNA (RIN >7 recommended) or poly(A)-enriched RNA. We offer enrichment and fragmentation options to accommodate various RNA types and experimental designs.
-
20 ng of poly(A) RNA or 250 ng total RNA
Please refer to our Shipping Guidelines for project-specific guidance.
Turnaround Time
Typical turnaround for RNA modification detection projects is 10–14 business days from sample receipt. Expedited options are available depending on project scope and sequencing depth.
Frequently Asked Questions (FAQs)
Q: What’s the difference between m6A and inosine modifications?
A: m6A is a methylation mark on adenosine that modulates RNA metabolism. Inosine arises from adenosine-to-inosine editing, typically impacting coding potential and splicing.
Q: Can this be done on noncoding RNAs or lncRNAs?
A: Absolutely. Our workflow captures both coding and noncoding transcripts, including long noncoding RNAs and circular RNAs.
Q: What makes this method different from traditional MeRIP-seq?
A: Unlike antibody-based MeRIP, EpiPlex uses non-antibody binders and barcoding technology to achieve higher specificity, less noise, and single-base resolution.
Q: Can this method quantify modification abundance?
A: Yes. Spike-in controls generate a standard curve for each sample, allowing relative quantitation of modification density.
Q: What modifications can you detect?
A: Currently, we offer high-resolution detection of m6A and inosine (A-to-I editing), with future capability for additional modifications.
Q: Can I combine this data with other transcriptomic analyses?
A: Yes. The data integrates seamlessly with RNA-seq, differential expression analysis, and pathway-level interpretation.
Q: How long is the turnaround time?
A: Standard turnaround is 3–4 weeks, depending on project scale and complexity.
Got more questions? Contact our team and get a free consultation anytime. info@augenomics.com
Glossary of Terms
-
m6A: N6-methyladenosine, the most abundant internal RNA modification in eukaryotic mRNAs
-
Inosine: A modified RNA base resulting from adenosine deamination, recognized as guanosine during translation
-
Epitranscriptomics: The study of chemical modifications on RNA molecules and their regulatory roles
-
MeRIP-seq: Methylated RNA immunoprecipitation sequencing, used to enrich and map m6A marks
-
A-to-I Editing: RNA editing event converting adenosine to inosine, catalyzed by ADAR enzymes
